These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18086413)

  • 1. HIV-1 integrase inhibitors: update and perspectives.
    Semenova EA; Marchand C; Pommier Y
    Adv Pharmacol; 2008; 56():199-228. PubMed ID: 18086413
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to HIV-1 integrase inhibitors: A structural perspective.
    Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
    Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to inhibitors of the human immunodeficiency virus type 1 integration.
    Hazuda DJ
    Braz J Infect Dis; 2010; 14(5):513-8. PubMed ID: 21221483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Raltegravir: the first HIV integrase inhibitor. Introduction].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():1-2. PubMed ID: 19572418
    [No Abstract]   [Full Text] [Related]  

  • 8. Integrase inhibitors in the treatment of HIV-1 infection.
    Powderly WG
    J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrase inhibitors.
    García-Gasco P; Blanco F; Soriano V
    J HIV Ther; 2005 Dec; 10(4):75-8. PubMed ID: 16519247
    [No Abstract]   [Full Text] [Related]  

  • 10. L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro.
    Reinke RA; Lee DJ; McDougall BR; King PJ; Victoria J; Mao Y; Lei X; Reinecke MG; Robinson WE
    Virology; 2004 Sep; 326(2):203-19. PubMed ID: 15302207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M; Chiarella J; Kozal MJ
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.
    Kehlenbeck S; Betz U; Birkmann A; Fast B; Göller AH; Henninger K; Lowinger T; Marrero D; Paessens A; Paulsen D; Pevzner V; Schohe-Loop R; Tsujishita H; Welker R; Kreuter J; Rübsamen-Waigmann H; Dittmer F
    J Virol; 2006 Jul; 80(14):6883-94. PubMed ID: 16809294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process.
    De Luca L; Gitto R; Christ F; Ferro S; De Grazia S; Morreale F; Debyser Z; Chimirri A
    Antiviral Res; 2011 Oct; 92(1):102-7. PubMed ID: 21767569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 integrase inhibitors: 2005-2006 update.
    Dayam R; Gundla R; Al-Mawsawi LQ; Neamati N
    Med Res Rev; 2008 Jan; 28(1):118-54. PubMed ID: 17979144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.
    Kobayashi M; Nakahara K; Seki T; Miki S; Kawauchi S; Suyama A; Wakasa-Morimoto C; Kodama M; Endoh T; Oosugi E; Matsushita Y; Murai H; Fujishita T; Yoshinaga T; Garvey E; Foster S; Underwood M; Johns B; Sato A; Fujiwara T
    Antiviral Res; 2008 Nov; 80(2):213-22. PubMed ID: 18625269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The integrase of the human immunodeficiency virus as a novel target for the antiviral therapy of AIDS.
    Witvrouw M; Debyser Z
    Verh K Acad Geneeskd Belg; 2003; 65(5):325-34. PubMed ID: 14671848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrase-independent HIV-1 infection is augmented under conditions of DNA damage and produces a viral reservoir.
    Ebina H; Kanemura Y; Suzuki Y; Urata K; Misawa N; Koyanagi Y
    Virology; 2012 May; 427(1):44-50. PubMed ID: 22374236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of HIV integration and therapeutic intervention.
    Vandegraaff N; Engelman A
    Expert Rev Mol Med; 2007 Feb; 9(6):1-19. PubMed ID: 17320002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.